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 Abstract 
 Diagnostic criteria for complex medical conditions caused by a multitude of both genetic and 
environmental factors should be descriptive and avoid any attribution of causality. Further-
more, the wording used to describe a disorder should be evidence-based and avoid stigma-
tization of the affected individuals. Both terminology and categorizations should be readily 
comprehensible for healthcare professionals and guide clinical decision making. Uncertainties 
with respect to diagnostic issues and their implications may be addressed to direct future 
clinical research. In this context, the European Association of the Study of Obesity (EASO) con-
siders it an important endeavor to review the current ICD-11 Beta Draft for the definition of 
overweight and obesity and to propose a substantial revision. We aim to provide an overview 
of the key issues that we deem relevant for the discussion of the diagnostic criteria. We first 
discuss the current ICD-10 criteria and those proposed in the ICD 11 Beta Draft. We conclude 
with our own proposal for diagnostic criteria, which we believe will improve the assessment 
of patients with obesity in a clinically meaningful way.  © 2017 The Author(s)
Published by S. Karger GmbH, Freiburg 
 Key Issues Relevant for the Delineation of Diagnostic Criteria for Obesity 
 The discussion and delineation of the diagnostic criteria for obesity requires a brief look 
at key issues to provide a background for the discussion of both the classification and wording 
of the ICD-10 and ICD-11 Beta Draft with respect to obesity  [1] . We have identified six main 
overarching key issues that we address for this purpose. For obvious reasons, the respective 
issues can only be addressed in a cursory manner; however, their focused delineation enables 
the reader to follow up our appraisal of the current status of the diagnostic criteria for obesity. 
 Definition of Obesity and Body Weight Categories 
 The World Health Organization (WHO)  [2] defines obesity as ‘a condition of abnormal or 
excessive fat accumulation in adipose tissue, to the extent that health may be impaired’. This 
definition linking abnormal or excessive fat accumulation with (potential) health impairment 
is at the core of the diagnostic uncertainties with respect to obesity. For one, abnormal or 
excessive fat accumulation is not specified or quantified; the use of the term abnormal can be 
perceived as being judgmental. Second, the terms fat and adipose tissue misleadingly portray 
the notion that both form a uniform mass. However, adipocytes in different regions and depots 
of the body are differentially regulated and fulfill different functions, some of which are bene-
ficial, some of which are detrimental to health. The distinctions between brown and white 
adipocytes, between ectopic and non-ectopic and between visceral and subcutaneous adipose 
tissue readily serve to illustrate the functional/metabolic/endocrine/developmental/cellular 
heterogeneity inherent to both adipocytes and adipose tissue accumulation. The complexity is 
compounded by the influence of age, gender, ethnicity, individual genetic and environmental 
factors. Third, the wording ‘to the extent that health may be impaired’ does not address how 
the link between abnormal or excessive fat accumulation and health is to be assessed.
 Which health aspects are relevant for the establishment of this link? According to the 
WHO  [3] , health is a state of complete physical, mental and social well-being, and not merely 
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the absence of disease or infirmity. However, to state that any physical, mental or social 
ailment associated with obesity qualifies obesity as a disease is not particularly helpful for 
clinicians who seek to narrow down the number of diseases/ailments that need to be screened 
for in any given patient; such a statement negates the clinical value of research to detect the 
mechanisms linking obesity to other diseases. Whereas indeed numerous mental and physical 
diseases have been determined to be associated with obesity, we posit that a physician should 
make use of this knowledge and assess a patient with obesity accordingly by e.g. knowing 
what comorbid disorders and  what associated risk factors should be screened for in any indi-
vidual patient of a given age, sex, ethnicity, family history, and personal medical history. 
Importantly, more than two-thirds of deaths related to a high BMI are due to cardiovascular 
disease  [4] . Finally, the definition does not require that health is currently impaired, ‘may’ 
indicates that an abnormal or excessive fat accumulation can represent a risk factor endan-
gering future health. The removal of the word ‘may’ has been suggested to indeed qualify 
obesity as a disease  [5] . 
 Based on the substantial correlation between BMI and fat mass upon assessment of a 
representative population sample, BMI (kg/m²) is widely used to assess adiposity. Paradoxi-
cally, the major limitation of the index is that it cannot distinguish fat from fat-free mass nor 
medically benign from medically harmful fat at the individual level. Over a wide range of the 
BMI distribution the BMI does not allow any conclusion as to its implications for health of the 
respective individual. As with many dimensional phenotypes, the extremes at both sides of 
the BMI distribution are of obvious medical concern including e.g. states of starvation such as 
those related to famines, anorexia nervosa, and disease-related cachexia/emaciation on the 
left and class III obesity (BMI  ≥ 40 kg/m²) at the right end. 
 The definitions and classifications of body weight categories have changed over time  [6] . 
The currently widely used weight classification of the WHO  [2] is based on the same BMI 
thresholds for adult males and females. Overweight is defined as a BMI equal to or in excess 
of BMI of 25 kg/m² and includes pre-obesity (25 to <30 kg/m²) and obesity ( ≥ 30 kg/m²); 
obesity in turn is subdivided into classes I (30 to <35 kg/m²), II (35.0 to <40 kg/m²) and III 
( ≥ 40 kg/m²). However, the definition of overweight is not used consistently. Unfortunately, 
the WHO Beta-Draft of ICD-11  [7] and others define overweight as the weight category encom-
passing the BMI range between 25 and <30 kg/m². Importantly, standard BMI groupings 
should be used to avoid problems of ad hoc and post hoc category selection and to facilitate 
between-study comparisons  [8] in order to assess the risks associated with specific body 
weight categories. 
 Overweight as defined via a BMI  ≥ 25 kg/m²  [2] occurs in more than 50% of most 
European and the US adult populations; obesity (BMI  ≥ 30 kg/m²) prevalence rates are in the 
magnitude of 20–30% in most (post)industrialized countries and also affect a substantial 
proportion of the populations of developing countries. Global adult obesity rates have doubled 
between 1980 and today  [9] : More than 1.9 billion adults ( ≥ 18 years) were overweight in 
2014, accounting for 39% of all adults. Of these, over 600 million were obese (13% of the 
world population). Alarmingly, rates have approximately tripled in youth and young adults, 
thus entailing a high risk for increased cumulative incidences of type 2 diabetes, hypertension, 
and chronic kidney disease  [4] ; currently the worldwide obesity prevalence among children 
is 5%  [4] .
 In conclusion, BMI is widely used to indirectly assess adiposity. However, over a wide 
BMI range the health implications of the BMI of a particular individual cannot be fathomed 
without further medical assessments. For this very reason, EASO has suggested to move 
beyond BMI  [10] and to personalize risk assessment. We nevertheless acknowledge the use 
of an operational BMI threshold (i.e., 30 kg/m² in Caucasian populations; other ethnicities 
may have lower thresholds due to increased risks for diseases associated with an excessive 
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fat mass) as an indicator of increased health risks; such a threshold should alert the physician 
to definitely pursue further medical assessments within the context of the somatic and 
psychological risks inherent to obesity. We also acknowledge that an individual with a BMI  ≥ 
30 kg/m² can be healthy and fit; due to elevated health risks such an individual should be 
monitored specifically for the development of obesity-related risk factors and diseases. The 
delineation of a BMI threshold entails the disadvantage that individuals with a BMI below the 
threshold will not be assessed in a similarly focused manner; a subgroup of these individuals 
may have elevated health risks and/or disease related to an elevated adiposity  [4] . Thus, 
physicians definitely need to medically assess individuals with a BMI < 30 kg/m² in the same 
manner, if their degree of adiposity is in the high range and/or if visceral adiposity is present. 
If such patients have medically pertinent disease related to their elevated adiposity, we 
recommend the diagnosis ‘pre-obesity’ in addition to the diagnosis of the respective disease. 
The diagnosis of pre-obesity will guide the physician with respect to monitoring and treatment 
of these individuals.   
 Health Risks Associated with Obesity 
 The BMI cutoff thresholds for adults were originally proposed in light of data indicating 
increased risks across the overweight range for associated medical disorders such as type 2 
diabetes mellitus, cardiovascular disease, and different types of cancers  [2] . The reported 
estimates for the population-attributable risks of obesity have been shown to range from 5 
to 15% for all-cause mortality, from –0.2 to 8% for all-cancer incidence, from 7 to 44% for 
cardiovascular disease incidence, and from 3 to 83% for type II diabetes mellitus incidence 
 [8] . 
 In 2013, the American Medical Association declared obesity a disease  [11] . Criticism of 
this far reaching step has centered on , e.g., the use of the BMI threshold of 30 kg/m² instead 
of an elevated waist-hip ratio to more precisely estimate associated medical risks and the 
fostering of a culture of individual irresponsibility; obesity can be viewed to merely represent 
a risk factor instead of a disease in itself  [12] . Sims in 2001  [13] asked ‘Are there persons who 
are obese, but medically healthy?’ and thus initiated discussions centering on the term ‘meta-
bolically healthy obese’. 
 A recent large scale meta-analysis  [14] based on a median follow-up of 13.7 years of 
almost 4 million people from Asia, Australia, New Zealand, Europe, and North America, who 
were never-smokers without chronic diseases at recruitment and who survived for 5 years, 
clearly revealed elevated sex-adjusted hazard ratios (HRs), relative to BMI 22.5–24.9 kg/m² 
throughout the overweight range (1.07 for BMI 25.0–27.49 kg/m²; 1.20 for BMI 27.5–29.9 
kg/m²; 1.45, 1.94 and 2.76 for obesity class I, II and III). Mortality increased approximately 
log-linearly with BMI over 25.0 kg/m² in all continents; this increment was greater in younger 
than older people (1.52 for BMI measured at 35–49 years vs. 1.21 for BMI measured at 70–89 
years) and greater in men than women (1.51 vs. 1.30). A BMI below 20 kg/m² was also asso-
ciated with an elevated sex-adjusted HR. 
 The mortality risk attributable to obesity needs to be set into relationship to other risk 
factors. A recent multi-cohort study and meta-analysis with individual-level data from 48 
independent prospective cohort studies revealed that low socioeconomic status was asso-
ciated with a 2.1-year reduction in life expectancy between ages 40 and 85 years; the corre-
sponding years-of-life-lost were 0.5 years for high alcohol intake, 0.7 years for obesity, 3.9 
years for diabetes, 1.6 years for hypertension, 2.4 years for physical inactivity, and 4.8 years 
for current smoking  [15] .
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 Irrespective of the elevated mortality, obesity is associated with a vast variety of somatic 
and to a lesser extent mental disorders, which do not necessarily entail elevated mortality, 
but clearly negatively impact growth, development, psychosocial adjustment, and/or health 
related quality of life. Indeed, it has been argued that the risks of obesity are much better 
explained as the risks of developing chronic conditions than by explaining mortality  [16] . 
Obesity-related disorders represent a major burden for healthcare systems of many coun-
tries.
 Substantial efforts have been made to better quantify the health risks associated with 
‘abnormal or excessive fat accumulation’ upon use of additional anthropometric measures 
(e.g. waist and hip circumferences, skinfold thickness), sums or ratios thereof, determination 
of specific serum risk factors, and technological methods (e.g. bioelectrical impedance, dual 
energy X-ray absorptiometry, air displacement plethysmography, imaging techniques). Their 
delineation and clinical value assessment are clearly beyond the scope of this article. From a 
clinical perspective, such measures/methods should be inexpensive, easy to implement, 
allow monitoring of the disease, and be readily interpretable; the use of sex-specific age 
centiles for anthropometric measures is strongly recommended; these should be based on 
the respective national and/or ethnic population. 
 We recommend the use of age-, sex- and ethnicity-appropriate thresholds for the defi-
nition of elevated adiposity, the consideration of regional distribution of fat mass, and the 
delineation of the associated health risks. Such measures should indeed substantially improve 
risk stratification beyond the use of BMI per se. At the same time, we need to strive for 
simplicity: if the diagnostic assessment becomes too complex, too expensive and/or the 
benefits of these assessments are ambiguous, we should opt for simple solutions. 
 Sharma and coworkers  [17, 18] introduced an obesity staging system based on the occur-
rence of risk factors, physical symptoms, psychopathology, functional limitations, and/or 
impairment of well-being related to obesity, importantly including obesity-related chronic 
disease and established end organ damage. Not surprisingly, this staging performed in US 
population-based individuals with a BMI  ≥ 25 kg/m² was clearly superior to risk assessment 
via use of the BMI weight categories pre-obesity and obesity classes I–III. 
 We definitely need to improve the capability to predict risk and disease, particularly in 
the absence of obesity-related chronic disease and end organ damage. This would represent 
a tremendous step forward; we require research to come up with age-, sex- and ethnicity-
dependent algorithms, which should in light of their importance include information on 
family history data, particularly including the occurrence and age of onset of obesity- related 
chronic conditions in parents and siblings and, in case of their death, the length of life. The 
respective variables should represent independent risk factors of a predefined magnitude. 
Variables to be tested include sex, age, socioeconomic status and educational attainment, 
anthropometric measures, laboratory results, heart rate and blood pressure, habitual dietary 
intake and level of physical activity, tobacco use, and family history data. We envision that 
physicians will be able to fill in a data sheet online to come up with estimates for health risks 
particular to the respective patient. We are convinced that the underlying algorithms will 
enable a substantially improved risk prediction beyond BMI.       
 To conclude, an elevated BMI is associated with health risks including many diseases 
 [19] . There is evidence to suggest that many of these health risks are at least in part causally 
related to an elevated level of adiposity, particularly if visceral adiposity is present. The health 
impact of obesity increases substantially across obesity classes I to III. A comparison with the 
risks imposed by other common and complex diseases is meaningful for guiding both 
treatment and prevention efforts. At the same time we note that obesity is a risk factor for 
several diseases that carry higher health risks than obesity itself. We see the research need 
for the development of readily applicable algorithms for the quantification of specific health 
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risks; BMI thresholds may prove helpful to determine what and the extent to which such risk 
factors require assessment. Physicians should be knowledgeable in these risk factors and 
diseases in order to accordingly guide the clinical assessment of a patient with obesity.     
 Developmental Aspects 
 The increments in prevalence rates for overweight and obesity have been particularly 
pronounced among children  [4] . 42 million children under the age of 5 were overweight or 
obese around the globe in the year 2013  [9] . Because obesity can track into adolescence and 
adulthood, children and adolescents with overweight and obesity require particular medical 
attention. As a rule of thumb, obesity tracks into adulthood with a greater likelihood if i) the 
child is older (adolescents > children), ii) the higher the BMI is in comparison to children of 
the same age, and iii) if one or both parents are obese  [20] . In young overweight/obese indi-
viduals some of the detrimental effects of an ‘abnormal or elevated fat accumulation’ may 
have a stronger impact over the lifespan than in adult onset obesity. Furthermore, obese 
adolescents are at a substantially elevated risk to develop class II and III obesity in adulthood, 
because the age-dependent increments in kg/m² are substantially higher in the upper as 
compared to the lower BMI centile range. 
 The WHO BMI-based weight categories for adults cannot be used for diagnosing obesity 
in children and adolescents. Instead, different cutoffs based on specific BMI age centiles as 
determined in reference populations have been used. In the US, overweight in children and 
adolescents is defined via the BMI age centile range between 85 and 95, obesity is defined as 
a BMI centile  ≥ 95  [21] . In Germany, BMI age centiles  ≥ 90 and  ≥ 97 are used to define over-
weight and obesity, respectively, in individuals aged  ≤ 18 years  [22] . In other countries, 
different definitions of childhood overweight and obesity based upon national references, 
and adaptations of international references are also used. Due to the BMI increase over the 
past 40 years, the definition of childhood overweight and obesity via BMI age centile cutoffs 
based on older reference populations entails that the current rates are characteristically 
higher than the respective centile cutoffs would suggest. Cross-country comparisons are 
hampered by the differences in absolute values that constitute BMI age- and sex-specific 
centiles, especially in the upper range. To date, age- and sex-specific definitions by the WHO 
and the International Obesity Task Force are available for use in clinical practice; they also 
enable the study of cross-country comparisons and allow determination of secular increases 
in rates of childhood and adolescent overweight and obesity  [23] .     
 Because BMI continues to increase in adulthood, the age of an adult patient with obesity 
also requires reflection. According to a representative German population sample surveyed 
in 2005/2006, 25.8% and 9.3% of the male as well as  20.7% and 7.2% of the female popu-
lation aged 18–19 years are overweight (BMI  ≥ 25 kg/m²) and obese (BMI  ≥ 30 kg/m²), 
respectively  [24] . In the eighth decade these numbers increase to lifetime maxima of 83.5% 
and 27.5% as well as 74.2% and 34.5%, respectively ( table 1 ). In adolescence and early 
adulthood, obesity is associated with more stigmatization with respect to social relationships 
and entry into the job market; a reduced self-esteem and other psychological problems as a 
consequence of excessive adiposity can ensue. Importantly, the obesity-related relative 
mortality risks decline with age  [14] . Furthermore, according to the obesity paradox, patients 
with obesity have a greater chance of surviving specific diseases/disorders that typically 
occur in late adulthood. Finally, particularly sarcopenic obesity, characterized by an increased 
adiposity and a relatively reduced muscle mass, warrants medical attention in view of the 
related health risks in the elderly  [25] . 
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 To sum up, obesity and its health risks cannot be judged adequately in both psychological 
and somatic terms without taking the age of a patient into account. Because in contrast to the 
WHO definitions of adult overweight (BMI  ≥ 25 kg/m²) and obesity (BMI  ≥ 30 kg/m²) over-
weight in children and adolescents is defined distinctly from obesity, we argue that a consistent 
definition be used. Depending on the wideness of the national BMI distribution, the respective 
BMI age centile cutoffs are  ≥ 85th or 90th and  ≥ 95th or 97th centiles for children or adolescents. 
In contrast to adults, we recommend that for children, and even more so for adolescents, over-
weight is also considered a disease if metabolic or cardiovascular risk factors can be detected. 
 Sex Differences 
 Both male and female sex hormones have well-known and profound influences on body 
fat distribution, ontogenetic pattern of fat accumulation, adipocyte function, development of 
the metabolic syndrome, and other health risks/diseases associated with obesity  [26] . In 
brief, females are predisposed to stronger subcutaneous fat deposition resulting in the gynoid 
or gluteal-femoral pattern of adipose tissue distribution (pear shaped), males to visceral fat 
(apple shaped). Puberty, pregnancy, and menopause in females exert strong effects on 
regional fat deposition and accumulation; developmental and pregnancy-induced changes 
represent risk periods for an increase in adiposity. As a consequence of these sex differences, 
men have a higher risk of metabolic syndrome and cardiovascular disease; after menopause 
the respective risks increase in females. Genetic factors that sex specifically influence BMI and 
body fat distribution have been detected  [27, 28] .
 Obesity in females of childbearing age warrants specific medical attention due to potential 
epigenetic and in utero effects in an embryo/fetus, which may increase the risk for obesity in 
 Table 1.  Relative frequency (%) of the WHO weight categories underweight, normal weight, pre-obesity, and 
obesity [2] and number of subjects per age group (German National Nutrition Survey; ascertainment: 2005–
2006) [24]
Sex Age, 
years
 BMI, kg/m2 N
<18 .5 18.5 ≤ BMI < 25.0 25.0 ≤ BMI < 30.0 ≥30.0
Females 18–19 7.2 72.1 13.5 7.2 208
20–29 5.5 68.2 17.7 8.6 746
30–39 3.3 62.7 21.0 13.0 1,221
40–49 1.0 52.8 28.7 17.5 1,626
50–59 0.5 43.8 33.0 22.7 1,264
60–69 0.6 32.1 37.8 29.5 1,312
70–79 0.7 25.1 39.7 34.5 701
total 2.1 48.3 29.3 20.3 7,078
Males 18–19 5.5 68.8 16.5 9.3 237
20–29 2.3 58.8 29.6 9.3 665
30–39 0.6 42.1 43.9 13.3 938
40–49 0.2 30.3 50.4 19.1 1,233
50–59 0.2 23.8 48.8 27.2 1,098
60–69 0.2 19.5 52.0 28.3 1,277
70–79 0.2 16.3 56.0 27.5 661
total 0.7 31.7 46.5 21.1 6,109
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the offspring beyond the inherited polygenic risk. Obesity in pregnancy is associated with 
higher risk of miscarriage, congenital malformations, and birth complications including still-
births. Due to intrauterine programming, elevated health risks for the offspring ensue. Obesity 
during pregnancy can also have short- and long-term adverse health consequences for the 
mother  [29] . Both female  [30] and male  [31] fertility is reduced in obesity.
 In conclusion, in addition to age, the sex of a patient with obesity is important with respect 
to the assessment of associated health risks. The implications of obesity in females of child-
bearing age for fertility, future pregnancy risks, and maternal and offspring outcomes need 
to be taken into account.
 Treatment: Relevant Aspects 
 Substantial evidence has accumulated indicating that body weight in humans is regulated 
in a homeostatic manner. This regulation is of particular concern to patients with obesity. 
While individuals who wish to lose weight are frequently successful in doing so, the medium- 
and long-term success of maintaining the achieved body weight is poor. The mechanisms 
underlying the weight regain require further elucidation  [32, 33] . Upon weight loss complex 
homeostatic counterregulatory adaptations set in, which result in a resting metabolic rate 
well below that of BMI-matched controls. This reduced resting metabolic rate has recently 
been shown to persist even 6 years after weight loss  [34] . For achievement of weight loss, a 
dietary intervention is more successful than an intervention aiming to increase the physical 
activity level; body weight management programs that combine diet and physical activity are 
seemingly more effective for weight loss over 12 months than interventions based on diet or 
physical activity alone  [35] . 
 The U.S. Prevention Services Task Force (USPSTF) concluded ‘with moderate certainty 
that the net benefit of screening for obesity in children and adolescents age 6 years and older 
and offering or referring them to comprehensive, intensive behavioral interventions to 
promote improvements in weight status and certain cardiometabolic factors is moderate’ 
(evidence grade B; draft recommendation statement)  [36] . The USPSTF  [37] had previously 
recommended screening all adults for obesity: Clinicians should offer or refer patients with 
a BMI of 30 kg/m² or higher to intensive, multicomponent behavioral interventions (also 
ranked as a grade B recommendation)  [37] . In light of the small long-term effects of conven-
tional weight loss programs, it has been argued that patients (and their caregivers) are 
informed accordingly prior to initiation of the program to allow for a decision based on real-
istic expectations  [38] . Unlike other major causes of preventable death and disability, there 
are no exemplar national populations in which the obesity epidemic has been reversed by 
public health measures  [39] . 
 The medium- and long-term results of bariatric surgery in terms of weight loss and 
weight maintenance have been shown to far surpass those of conventional weight loss 
programs  [40] . Bariatric surgery for obesity class III or obesity class II associated with obesity-
related comorbid disease also results in the improvement and remission of several comorbid 
conditions, and quality of life is improved  [41] . Mortality rates have been shown to be lower 
after bariatric surgery in comparison to patients of the same BMI range, who did not forego 
surgery  [42] . The WHO weight categorization  [2] has been used to define eligibility for 
bariatric surgery, which commonly represents a treatment option for patients with a BMI  ≥ 
40 kg/m² (obesity class III) or a BMI  ≥ 35 kg/m² with coexisting medical conditions. Never-
theless, we acknowledge that the access to bariatric surgery should not overly rely on specific 
BMI thresholds; it is the disease state of an individual patient that merits consideration. 
Indeed, recent clinical guidelines on obesity management do not consider BMI as a solo risk 
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factor or single indicator for the need to intervene  [43] . The necessity for obesity management 
is defined by BMI, waist circumference, and comorbid disease(s). 
 A section on relevant treatment aspects is incomplete without reference to weight stigma 
 [44] , which is very frequent in diverse healthcare settings including physicians and even 
obesity specialists. In comparison to normal-weight patients, healthcare professionals spend 
less time in consultation with patients with obesity, thus entailing a reduced access to 
treatment. This may have a deleterious impact on patients with severe consequences: negative 
body image, poor self-esteem, avoidance of physical activity, increased risk of eating disorders, 
depression, and even suicidal ideations. Patients have the feeling of not being esteemed by 
their physician so that they may cancel their consultation and as a result receive less medical 
care, thus further increasing health risks. Children are particularly prone to weight stigmati-
zation and teasing. Some success in decreasing stigmatization has been achieved  [45] by 
appropriate education of healthcare professionals and medical students. The key message is 
that weight status and obesity are not under personal control. In the interaction with patients 
motivational interviewing has proven useful to avoid stigma. Motivational interviewing is a 
guided, patient-centered, non-judgmental and respectful counseling style. The medical 
equipment in the medical practice should be adapted to the needs of patients with obesity 
(e.g., appropriate blood pressure cuffs, scales, chairs without armrests); discrete weighing 
procedures should be offered in a private location.
 Complex Etiology 
 Obesity results from a positive energy balance maintained over a prolonged period of 
time. The mechanisms underlying this positive energy balance are numerous, complex and to 
a large extent beyond willful control; they may only partially overlap between individual 
patients with obesity. As such, obesity is a multifactorial condition. Heritability of BMI is esti-
mated at around 0.6 to 0.8 as based on twin studies and is similar across pre-adolescence into 
late adulthood  [46] ; unique environmental factors explain most of the environmental 
influence. The most recent meta-analysis of genome wide association studies identified 97 
BMI loci which surpassed the criterion for genome wide significance  [47] . Some of the 
respective alleles alter body weight by less than 200 g. The respective alleles act in an additive 
manner to explain approximately 3% of the total BMI variation in a given population; non-
additive mechanisms have yet to be elucidated at the molecular level. We have just begun to 
investigate non-additive gene-gene or gene-environment interactions.
 Single forms of monogenic obesity and syndromal obesity have been delineated. The 
respective elucidations have provided us with valuable insights into important central 
pathways for the regulation of body weight. In total, these forms of obesity account for 2–4% 
of all individuals with obesity, amongst whom carriers of functionally relevant melano-
cortin-4 receptor gene mutations account for a large proportion. This autosomal dominant 
form of obesity has been shown to increase adult body weight by approximately 15 and 30 
kg in males and females, respectively  [48] . Autosomal recessively inherited leptin deficiency 
is the only form of monogenic obesity that can be treated causally via leptin replacement 
therapy  [49] . 
 Environmental factors (including our microbiome) play a crucial role for the devel-
opment of obesity. However, within any given society the obesogenic environment may not 
differ that much entailing that genetic factors play a substantial role in explaining BMI variance 
of the respective population. It has proven difficult to dissect single environmental factors 
which beyond any doubt exert an influence on BMI. A sedentary lifestyle and overconsumption 
of foods are perceived as major players. Changes in the global food system, which is producing 
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palatable, more processed, cheap, and effectively marketed food, are thought to entail ‘passive’ 
overconsumption of energy. Overweight and obesity can thus be viewed as a predictable 
outcome of market economies predicated on consumption-based growth  [39] . Social class is 
a predictor of body weight in industrial and developing countries – albeit with partially 
opposite effects  [50, 51] . 
 Obesity can be potentially amenable to treatment if a major underlying cause can be iden-
tified. Thus, physicians need to be aware of specific diseases that may underlie excessive 
weight gain entailing obesity. A major depressive episode may entail weight gain, which can 
result in obesity; atypical depression is a subtype of depression which amongst other 
symptoms is frequently associated with weight gain. Immobilization can entail weight gain in 
thus predisposed individuals. Importantly, physicians should be alerted to the common 
occurrence of weight gain upon prescription of drugs that entail significant weight gain as a 
side effect, potentially leading to iatrogenic obesity . Obesity is also a well-established compli-
cation of hypothalamic surgery. 
 In conclusion, for the vast majority of individuals with obesity we cannot diagnose a 
major underlying cause. This type of obesity is best termed multifactorial; physicians need to 
understand that the predisposing genetic and environmental risk factors as well as their 
interactions only partially overlap between patients. We stress the importance to attempt 
identifying a major cause underlying the obesity of a patient because of potential therapeutic 
and prognostic implications. By doing so, we acknowledge the impossibility to indeed causally 
attribute the obesity of a patient to a major cause beyond any doubt in many cases; we provide 
guidelines for delineation of both the time frame and the weight increment to occur in obesity 
of a certain defined etiological factor; further research is required to validate the respective 
criteria. We have delineated single major factors, which must be viewed as provisional and 
are perceived as useful to guide future research; these factors are marked as such.   
 A Look at the Current Classification Scheme ICD-10 
 In ICD-10  [52] , obesity was coded within the parent category ‘Endocrine, nutritional and 
metabolic diseases’ (E00–99;  table 2 ). This parent term readily reflected the uncertainty 
pertaining to the classification of obesity, which was lumped together with endocrine, nutri-
tional and metabolic diseases. Whereas endocrine, nutritional and metabolic factors obvi-
ously play a role in the development of obesity, other important factors such as energy expen-
diture or a sedentary or inactive lifestyle were not referenced. Due to inclusion of obesity 
within nutritional disorders, overt emphasis was placed on nutrition. 
 Obesity was subcategorized into ‘Obesity due to excess calories’ (E66.0), ‘Drug-induced 
obesity’ (E66.1), ‘Extreme obesity with alveolar hypoventilation’ (E66.2), ‘Other obesity’ 
(E66.8), and ‘Obesity, unspecified’ (E66.9)  [52] . It is surprising that the subcategories were 
termed in this seemingly haphazard way, perhaps reflecting the former professional neglect 
Endocrine, nutritional and metabolic diseases (E00-E90) 
E65–68 Obesity and other hyperalimentation
E66 Obesity
 E66.0 Obesity due to excess calories
 E66.1 Drug-induced obesity
 E66.2 Extreme obesity with alveolar hypoventilation
 E66.8 Other obesity (morbid obesity)
 E66.9 Obesity, unspecified
 Table 2.  Current classification of 
obesity according to the 
International Statistical 
Classification of Diseases and 
Related Health Problems 10th 
Revision (ICD-10) – WHO 
Version for 2016 [52]
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of obesity and the ignorance of its relevance. The subcategorization pertained to (assumed) 
causes, descriptive terms with a focus on comorbidity and the degree of obesity (morbid 
obesity was to be coded as ‘Other obesity’). We are unable to diagnose ‘Obesity due to excess 
calories’, because we do not have a routine clinical method to determine the caloric intake of 
an individual. In addition, the sole reference to an excess caloric intake negates the complexity 
of the systems regulating both energy intake and expenditure; physical inactivity was not 
mentioned within the context of obesity. An excess energy intake relative to energy expen-
diture characterizes all types of obesity. The subcategories have made neither intuitive, 
logical nor professional sense and thus provided little guidance to the clinician.      
 Critical Reflection on Overweight and Obesity within the Current ICD-11 Beta 
Draft  
 Table 3 provides an overview of the classification and terminology used to describe over-
weight and obesity in the WHO ICD-11 Beta Draft  [7] . Overweight and obesity are again cate-
gorized within ‘Nutritional disorders’, which as in ICD-10 belong to the parent ‘Endocrine, 
nutritional and metabolic diseases’. As such, overweight and obesity continue to be concep-
tualized as nutritional disorders; this does not appear appropriate in light of the complexity 
of the mechanisms causally involved in development of an elevated BMI. The definition 
provided for the subcategory ‘Overweight, obesity and specific nutrient excesses’ is rudi-
mentary and contrasts markedly with the detailed definitions given for e.g. specific genetic 
syndromes. The term ‘body size is excessive’ appears to stigmatize more than 50% of the 
population in many countries. Body composition or body fat distribution is not addressed, 
nor is any distinction made between fat-free and fat mass.  
 ‘Macro intake’ is not a clearly defined biomedical term. It is unclear if this term refers to 
macronutrients. The meaning of an ‘excess in energy and/or macro intake’ is not readily 
comprehensible; the term by itself is not meaningful without referring to energy expenditure. 
Overweight and obesity are typically thought to ensue via an excess energy (or macronu-
trient) intake, if the total energy intake indeed exceeds energy expenditure over a prolonged 
period of time. The complex wiring of the neuroendocrine and physiological systems involved 
in body weight regulation has evolved to enable survival during famines; the systems are not 
geared to deal with the obesogenic environment of today. Including overweight/obesity 
within the category ‘Nutritional disorders’ does not reflect the potential contribution of a low 
energy expenditure due to a low resting metabolic rate and/or physical inactivity. Nutrients 
and in particular their intake merely represent one side of the energy balance relevant for the 
development of these weight categories. 
 The first category within the parent ‘Overweight, obesity and specific nutrient excesses’ 
is ‘Overweight and obesity’. In contrast to other WHO definitions, the ICD-11 Beta-Draft  [7] 
restricts the term overweight to the BMI range 25.0 to 29.9 kg/m²; previously, this BMI range 
has been defined as pre-obesity and overweight was used to define the range  ≥ 25 kg/m² and 
as such included obesity (see above). Because the scientific literature uses the term over-
weight for both pre-obesity and a BMI  ≥ 25 kg/m², ICD 11 should take special care to clearly 
address this inconsistency and to provide a clear solution/definition; we favor adherence to 
the categorization proposed by the WHO in 2000  [2] .
 We pointed out the recent inclusion of obesity as a disease by the American Medical Asso-
ciation  [11] . The ICD-11 Beta Draft  [7] opens the door further by including overweight as a 
disease; however, pre-obesity more appropriately represents a risk factor for the devel-
opment of obesity and/or of disorders associated with obesity. The medicalization of this 
common weight category overweight may decrease the motivation of healthcare profes-
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sionals to code overweight and to pay specific attention to the medical needs of patients with 
obesity. We propose to reserve the diagnosis of pre-obesity to individuals with an elevated 
adiposity, who have developed a metabolic and/or cardiovascular disease (see below); in 
children and adolescents the detection of any metabolic and/or cardiovascular risk factor 
related to an elevated adiposity merits the diagnosis of pre-obesity.
 The problem inherent to the inclusion of overweight in the Beta Draft is compounded by 
the subcategory ‘Risk of overweight in infants or children up to five years of age’, which 
 Table 3.  Classification of overweight and obesity in the ICD-11 Beta Draft [7]* 
06 Endocrine, nutritional or metabolic diseases
Nutritional disorders 
 Overweight, obesity and specific nutrient excesses
 Overweight and obesity
  Overweight and localized adiposity
   Overweight
    Overweight in infants, children or adolescents  
     Risk of overweight in infants or children up to 5 years of age  
     Overweight in infants or children up to 5 years of age
     Overweight in school-aged children or adolescents, 5 to 19 years  
     Overweight in adults
   Localized adiposity
   Fat pad
   Benign symmetrical lipomatosis
    Narrower Terms: Familial benign cervical lipomatosis
   Obesity
    Obesity due to energy imbalance  
    Obesity in children and adolescents 
     Obesity in infants or children up to 5 years of age  
     Obesity in school-aged children or adolescents from 5 to 19 years
    Obesity in adults
     Obesity with BMI 30.00–34.99  
     Obesity with BMI 35.00–39.99
     Obesity with BMI greater than or equal to 40.00
  Drug-induced obesity  
   Obesity hypoventilation syndrome
   Leptin-related genetic obesity  
   Obesity due to congenital leptin deficiency
   Obesity due to congenital leptin resistance
    Obesity due to prohormone convertase-1 deficiency
    Obesity due to leptin receptor gene deficiency
    Obesity due to pro-opiomelanocortin deficiency  
    Obesity due to melanocortin-4 receptor deficiency
  Syndromes with obesity as a feature
    Alström syndrome
    Börjeson-Forssman-Lehmann syndrome  
    Cohen syndrome  
    MEHMO syndrome 
    Obesity due to 6q16 deletion  
    Prader-Willi syndrome  
    Sotos syndrome 
    Weaver syndrome  
    Wilson-Turner syndrome  
    Beckwith-Wiedemann syndrome
 *For complete version see WHO, ICD-11 beta draft (accessed May 31, 2017) [7]. 
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clearly lists a risk factor, and not a disease. Using this definition, slightly more than 13% of all 
infants and young children would fulfill the given centile range from 84.1 to 97.7; a substan-
tially higher number is at ‘risk of overweight’ if an older reference sample is used. Use of a 
centile cutoff value with a decimal is not helpful for clinicians; the complex information given 
to correctly assess length/height is not readily transferable to routine clinical assessments.   
 The subcategory ‘Overweight and localized adiposity’ and its two sub-definitions appear 
problematic because the term localized adiposity is not a common clinical diagnosis; the term 
should not be used in the classification scheme due to difficulties in clearly defining such a 
regional adipose tissue mass. If ‘fat pad’ and ‘benign symmetrical lipomatosis’ warrant diag-
nostic representation, they should not be listed together with overweight. 
 The centiles provided in the ICD-11 Beta Draft for a definition of ‘Risk of overweight in 
infants or children up to five years of age’, ‘Overweight in infants or children up to five years 
of age’, and ‘Overweight in school-aged children or adolescents, 5 to 19 years’ change. Whereas 
the first and third subcategory are based on the same centile cutoffs, ‘Overweight in infants 
or children up to five years of age’ entails a more severe degree of adiposity. The complexity 
of this classification of infant, childhood and adolescent obesity will likely not take off among 
pediatricians and general practitioners – it is just too impractical; furthermore, as a child 
transverses the age range from month 60 to 61, a different centile cutoff applies. Only the 
definition of a narrowly defined obesity appears meaningful in infants and children up to age 
5. At this developmental stage excess adiposity does not entail substantially elevated risks for 
the development of late childhood, adolescent or adult obesity; even ‘obesity’ in infancy or 
early childhood does not track well into later life, unless one or both parents are obese  [53] . 
 Obesity is subdivided into ‘Obesity due to energy imbalance’, ‘Drug-induced obesity’, 
‘Obesity hypoventilaton syndrome’, ‘Leptin-related genetic obesity’, and ‘Syndromes with 
obesity as a feature’. All five appear to relate to different mechanisms underlying the devel-
opment of obesity. However, an ‘energy imbalance’ also underlies the development of ‘Drug-
induced obesity’, ‘Leptin-related genetic obesity’, and the ‘Obesity hypoventilation syndrome’, 
which does not represent a well-defined medical entity; the definition given in the ICD-11 
Beta Draft version may warrant an alternative inclusion among disorders of the lung and in 
particular alveolar hypoventilation. Undoubtedly, drug-induced weight gain can represent a 
serious problem for individuals who require medication with this side effect. Nevertheless, 
caution is warranted because a drug-induced weight gain of 15 kg in a lean patient with 
underweight at baseline may represent a much more serious problem than a 1-kg weight gain 
in an individual who had a BMI marginally below 30 kg/m² upon initiation of the medication. 
Overall, it appears somewhat problematic to classify side effects of medications within ICD-11, 
the major question being where to draw a line – what medication side effects warrant their 
listing as a disease entity? The inclusion of ‘Leptin-related genetic obesity’ appears prob-
lematic because confirmation by genetic testing is required; just recently, mutations in the 
leptin gene were detected that do not entail leptin deficiency  [54] , implying that in theory the 
leptin gene would have to be screened for functionally relevant mutations in all patients with 
extreme obesity, which is not readily feasible. Furthermore, the text lists mutations in the 
peroxisome proliferator-activated receptor gamma gene which are not directly related to 
leptin. Physicians should not find disorders in a clinical classification scheme that have only 
rarely been reported; according to the Beta Draft ‘Obesity due to prohormone convertase-I 
deficiency’ has only been described in two patients (this statement is incorrect). Instead, an 
overall classification scheme should take single entities with a major single genetic cause of 
obesity into account. 
 A BMI for age above three standard deviations of the median (z-score  ≥ 3) is used to 
diagnose ‘Obesity in infants or children up to five years of age’; in the older group two standard 
deviations represent the cutoff. Pointing out the equivalent of this cutoff at age 19 to a BMI of 
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30 kg/m² needs to be reflected upon critically because at this age and during young adulthood 
the prevalence of obesity is substantially lower than in older adults. However, young adults 
with a BMI of 28 or 29 kg/m² already have a substantial risk for obesity-related comorbid-
ities. In addition, they are at an elevated risk to develop class II and III obesity. 
 EASO Proposal for the ICD-11 Classification of Obesity 
 In  tables 4 and  5 , we propose a classification of obesity that is more consistent with 
current terminology and definitions. The classification enables the clinician to logically, 
professionally and intuitively grasp the subdivisions. We propose a separate overarching 
parent termed ‘Obesity’ to indicate that obesity should not be listed with endocrine and meta-
bolic diseases; obesity is too common and too complex to remain within this category, in 
particular because the causal link to endocrine and metabolic disease may be weak in many 
patients (i.e., inactivity). Obesity should not constitute a subcategory of nutritional disorders 
(see above). Children, adolescents and adults are dealt with within each diagnostic category 
within the parent ‘Obesity’. 
 The diagnosis of obesity rests on a BMI  ≥ 30 kg/m² (in non-Caucasian populations other 
cutoffs are appropriate to define similar health risks); however, the physician must ensure 
that an elevated adiposity constitutes a substantial proportion of the body weight of the 
respective patient. Thus, whereas the BMI cutoff  ≥ 30 kg/m² serves as a useful operational 
 Table 4.  Proposal for the structure of the classification of obesity in ICD-11
06 Endocrine, nutritional and metabolic diseases 
07 Obesity
Dimension 1: Etiology
Obesity, multifactorial  
Obesity attributable to a certain defined etiological factor
 Obesity, iatrogenic
 Obesity arising from or aggravated by drug induced weight gain 
 Obesity arising from or aggravated by other iatrogenic procedures
 Obesity arising from or aggravated by a certain defined disease/condition 
 Obesity arising from or aggravated by a certain defined endocrine disease 
  Obesity arising from or aggravated by a certain defined neoplasm
 Obesity arising from or aggravated by major depressive disorder
 Obesity arising from or aggravated by immobilization/inactivity
 Obesity attributable to more than one certain defined etiological factor
 Obesity due to monogenic disease / genetic syndrome
 Obesity due to other major causes
Dimension 2: Degree of adiposity
Obesity class I
Obesity class II
Obesity class III
Obesity class IV
Obesity class V
Obesity class VI
Dimension 3: Health risk
Low
Intermediate
High
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 Table 5.  Proposal for the classification of obesity in ICD-11
07 Obesit y
Dimension 1: Etiology
Obesity, multifactorial  
This category is to be used for patients with obesity, for which no certain defined etiological factor can be identified. For 
these patients obesity is the result of complex interactions of a large number of genetic and environmental factors, some 
of which can be identified (e.g. predisposing genetic variants with small effect sizes). Obesity, multifactorial applies to the 
majority of patients with obesity. Weight gain can be pronounced during specific time periods (e.g. puberty, post-
pregnancy, or menopause). In medical terms, obesity is important because it is associated with a large number of somatic 
(including e.g. type 2 diabetes mellitus, cardiovascular disease, metabolic syndrome, diverse types of cancer, 
musculoskeletal disease) and to a lesser extent mental diseases (e.g. major depressive disorder), which if applicable 
should be coded separately; in general, risks for these associated diseases increase with increasing BMI. It is noteworthy 
to point out that a considerable number of the individuals with obesity are metabolically healthy; however, due to the 
increased health risks of such individuals a heightened medical surveillance is advised. This applies all the more so for 
younger individuals. Health care professionals need to be aware of the complexity of body weight regulation; importantly, 
after intentional weight loss a complex counter-regulation sets in, that results in an energy expenditure well below that of 
other BMI matched controls for extended periods of time. Accordingly, most patients with obesity have substantial 
difficulties with weight maintenance after achievement of conservative weight loss. 
Definition: Obesity in adults is most frequently defined via a BMI ≥ 30 kg/m² in many Caucasian populations; in some 
non-Caucasian (e.g. Asian) populations a lower threshold is applicable. An elevated adiposity is understood as an elevated 
fat mass as a prerequisite for the diagnosis of obesity. The use of additional anthropometric measures and/or techniques 
is strongly recommended to substantiate the elevated adiposity; age, sex and ethnicity need to be taken into account to 
interpret the respective measures/results. Particularly, visceral fat accumulation entails elevated risks for the 
development of several obesity associated diseases, which include metabolic diseases and type 2 diabetes mellitus in 
particular, cardiovascular disease and various types of cancers. The measurement of waist circumference as a surrogate 
marker of visceral fat is strongly recommended to estimate the risk for the development of such diseases; in addition the 
medical assessment of such a patient should include measurement of blood pressure and determination of blood glucose 
and lipids; in males and females of European origin the risk for metabolic disorders is increased or substantially increased 
if weight circumference equals or exceeds 94 and 102 cm, and 80 and 88 cm, respectively (WHO, 2000); other cutoffs are 
applicable to patients of other ethnicities. Globally, rates of obesity have increased over the last decades and in multiple 
countries obesity now occurs in more than 20% of the adult population. The proportion of the adult population with a 
BMI ≥ 30 kg/m² is typically rather low in young adulthood and substantially higher in later decades of life. As a rule of 
thumb, a BMI of 30 kg/m² in an 18-year-old is of substantially greater medical concern with respect to the medium and 
longer term development of medical sequelae than the same BMI in a 50 or 60 year old patient.
For children and adolescents BMI age centiles for both boys and girls are available in many countries. The 95th or 97th 
BMI age centiles (approximately equivalent to +2 standard deviations; for simplicity we subsequently refer to the 95th) 
are often used as thresholds for the diagnosis of obesity in children and adolescents. Absolute BMI values, that constitute 
a particular BMI centile in the upper range, can vary considerably between countries, thus rendering cross-country 
centile based comparisons difficult. Because the mean BMI of children and adolescents has increased also over the past 
decades, care must be applied upon the use of recent population based samples to avoid an underestimation of obesity 
prevalence rates. Adolescent BMI tracks into adulthood; in contrast, the BMI in infancy tracks little into adolescence and 
adulthood. In general terms, the likelihood that an age adjusted elevated BMI of individuals aged less than 18 years  
predicts adult obesity, is higher the older the individual and the higher the age adjusted BMI at baseline. The risk is 
further increased if one or both parents are obese. In principle, the medical risks associated with obesity apply to children 
and adolescents as well; for several obesity-related diseases they are increased in comparison to those observed in adults. 
Children, adolescents and young adults with obesity are particularly prone to weight related teasing and other types of 
stigmatization.  
Binge eating can be associated with Obesity, multifactorial. If the criteria for Binge Eating Disorder are met, this disorder 
is to be coded additionally. 
Table 5 continued on next page 
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definition for obesity, we agree that it should not be used as the conceptual definition  [55] . 
Further research is required to improve the operational definition of obesity. The diagnosis 
of obesity is warranted, irrespective of whether obesity-related diseases are present or not. 
The physician must use additional anthropometric measures or technical procedures to 
substantiate the elevated adiposity; the use of sex-and age-specific centiles is strongly recom-
mended, which should if possible be based on the respective ethnic population. We 
acknowledge that we currently do not have a ‘one size fits all’ definition for elevated adiposity, 
particularly because the regional fat distribution is very important for delineation of the 
health risks associated with obesity.
Table 5. Continued
07 Obesity
Obesity attributable to a certain defined etiological factor
It is important to recognize an underlying certain defined etiological factor in the development of obesity, because such a 
factor may require a specific medical approach. This diagnostic category should be used only if the specific etiological 
factor can be established without reasonable doubt. Quantitative criteria to establish a clinically relevant weight gain are 
provided where appropriate.    
Obesity, iatrogenic
Obesity arising from or aggravated by drug induced weight gain
The diagnosis of Obesity arising from or aggravated by drug induced weight gain requires 1) a BMI ≥ 30 kg/m² in 
adults or ≥ 95th centile in children and adolescents and elevated adiposity, 2) a noticeable and clinically relevant drug 
induced weight gain exceeding 5% of body weight at baseline within a 4-month period upon initiation of the drug 
treatment beyond any reasonable doubt, 3) the respective drug (or a set of different drugs) is known to induce weight 
gain as a side effect, 4) the weight gain cannot be attributed to another etiological factor. 
Because several medications – common examples include insulin (treatment of both type 1 and 2 diabetes mellitus), 
glucocorticoids and some anticonvulsants and psychotropic drugs (specific antipsychotics, antidepressants, anti-
anxiety agents, and mood stabilizers) – can induce weight gain in predisposed individuals, drug-induced obesity 
represents a comparatively common major cause of obesity. Drug induced weight gain may negatively affect 
adherence to the respective medication (scheme). A careful assessment of current and previous medication use is 
warranted in individuals with obesity. If feasible, medication should be switched to a substance that does not induce 
this side effect. Weekly weight monitoring is important for individuals who are newly prescribed medications that are 
known to frequently induce weight gain.
Patients with Obesity arising from or aggravated by drug induced weight gain will as a rule have one or more 
additional disorders that led to the respective drug treatment; this disorder(s) should be coded accordingly.  
Obesity arising from or aggravated by other iatrogenic procedures
The diagnosis of Obesity arising from or aggravated by other iatrogenic procedures requires 1) a BMI ≥ 30 kg/m² in 
adults or ≥ 95th centile in children and adolescents and elevated adiposity, 2) a noticeable and clinically relevant drug 
induced weight gain exceeding 5% of body weight at baseline within a 3-month period induced by an iatrogenic 
procedure other than the prescription of a drug, 3) the respective procedure is known to induce weight gain as a side 
effect, 4) the weight gain cannot be attributed to another etiological factor.
Relevant examples include neurosurgical procedures involving the hypothalamus (e.g. due to resection of a 
craniopharyngioma) and radiation therapy for brain tumors. Obesity due to other iatrogenic factors explains only a 
very small proportion of obesity in the general population. Nevertheless, the causal link to the respective procedure 
and the association with the underlying condition warrant this distinct diagnostic category.  
Patients with Obesity arising from or aggravated by other iatrogenic procedures will as a rule have a disorder that led 
the physician to use the respective procedure; this disorder should be coded accordingly.  
Obesity arising from or aggravated by a certain defined disease/condition 
This category is reserved for patients with defined diseases, in whom noticeable and clinically relevant weight gain 
results in obesity or aggravates existent obesity. The respective disease/condition is known to directly or indirectly 
underlie the weight gain.  
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 Reference to overweight was omitted as this weight category is based on a BMI  ≥ 25 
kg/m² and thus includes the BMI range for obesity (WHO  [2] ). We reserve the diagnosis ‘Pre-
obesity’ (25.0 < BMI < 30 kg/m² in Caucasian populations) for those adult patients who addi-
tionally have a metabolic and/or cardiovascular disease related to an elevated adiposity, 
acknowledging that the link to elevated adiposity does not necessarily imply causality (e.g., 
physical inactivity or other lifestyle-related factors may represent the major or part of the 
causal link in a subgroup). The link to only metabolic and cardiovascular diseases pays 
reference to those diseases, whose occurrence risks attributable to elevated adiposity are 
Table 5. Continued
07 Obesity
Obesity arising from or aggravated by a certain defined endocrine disease 
The diagnosis of Obesity arising from or aggravated by a certain defined endocrine disease requires 1) a BMI ≥ 
30 kg/m² in adults or ≥ 95th centile in children and adolescents and elevated adiposity, 2) a noticeable and 
clinically relevant weight gain exceeding 10% of premorbid body weight induced by a certain defined 
endocrine disease, 3) the respective endocrine disease is known to induce weight gain, 4) the weight gain 
cannot be attributed to another etiological factor.
Endocrine disease entailing significant weight gain is frequently associated with other symptoms potentially 
also including a reduced growth in height, the combination of which may pave the way to the respective 
diagnosis. Relevant examples include Cushing’s disease, growth hormone deficiency and hypothyroidism. The 
respective disorder should be coded separately. 
Obesity arising from or aggravated by a certain defined endocrine disease explains only a small proportion of 
obesity in the general population. Nevertheless, the associated clinical symptoms and the potential treatment 
of the endocrine disease warrant this distinct diagnostic category.  
The underlying endocrine disease requires a separate coding.   
An endocrine active neoplasm (e.g. pituitary adrenocorticotropin hormone (ACTH)) and paraneoplastic 
syndromes, which have induced noticeable weight gain, should be coded as both Obesity arising from or 
aggravated by a certain defined endocrine disease and Obesity arising from or aggravated by a certain defined 
neoplasm. Similarly, monogenic disorders/genetic syndromes, which result in an endocrine disease that 
causally induces weight gain (e.g. leptin deficiency or leptin receptor mutations), should be classified here; in 
addition, in these rare cases Obesity due to a monogenic disorder/genetic syndrome should also be coded. 
Obesity arising from or aggravated by a certain defined neoplasm
The diagnosis of Obesity arising from or aggravated by a certain defined neoplasm requires 1) a BMI ≥ 30 kg/
m² in adults or ≥ 95th centile in children and adolescents and elevated adiposity, 2) a noticeable and clinically 
relevant weight gain exceeding 10% of premorbid body weight induced by a certain defined neoplasm, 3) the 
respective neoplasm is known to induce weight gain, 4) the weight gain cannot be attributed to another 
etiological factor. Craniopharyngeomas and tumors of the hypothalamus represent an example for this 
diagnostic category.
Obesity arising from or aggravated by a certain defined neoplasm explains only a small proportion of obesity in 
the general population. Nevertheless, the associated clinical symptoms and the potential treatment of the 
neoplasm warrant this distinct diagnostic category.  
Rarely, a tumor can have a significant tumor mass, which can lead to the diagnosis of Obesity arising from or 
aggravated by a certain defined neoplasm. A hypothalamic tumor that promotes overeating should also be 
classified here. Finally, this diagnosis is warranted in addition to that of Obesity arising from or aggravated by 
a certain defined endocrine disease if the neoplasm directly or indirectly induces weight gain via an endocrine 
mechanism. If the endocrine active neoplasm is the result of a monogenic disorder (e.g. multiple endocrine 
neoplasm I and II), a third diagnosis of Obesity due to monogenic disorders/genetic syndromes is warranted.    
The underlying neoplasm requires a separate coding.  
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high. Because the increase in all-cause mortality is rather low for the BMI range 25–29.9 
kg/m² in comparison to the BMI range 20–24.9 kg/m², we do not diagnose ‘Pre-obesity’ in 
the absence of metabolic and/or cardiovascular diseases. However, physicians must recognize 
this BMI range as a risk factor for the development of obesity and related disorders, particu-
larly in younger adult patients. 
 In children and adolescents, ‘Pre-obesity’  (BMI centile between 85 and 95 or 90 and 97 
in Caucasian populations) is to be additionally diagnosed in patients with any type of meta-
bolic and/or cardiovascular risk factor associated with an elevated adiposity.  
Table 5. Continued
07 Obesity
Obesity arising from or aggravated by major depressive disorder
The diagnosis of Obesity arising from or aggravated by major depressive disorder requires 1) a BMI ≥ 30 kg/m² 
in adults or ≥ 95th centile in children and adolescents and elevated adiposity, 2) a noticeable and clinically 
relevant weight gain exceeding 10% of body weight within 6 months of one or more major depressive 
episodes, 3) the weight gain cannot be attributed to another etiological factor; in particular, a diagnosis of 
Obesity arising from or aggravated by drug induced weight gain needs to be excluded. An increased appetite 
and/or weight gain and/or a decreased activity level represent symptoms of a major depressive episode. As 
such, a subgroup of patients with major depressive disorder develops obesity; atypical depression is a 
frequently used diagnostic label for this subgroup. 
The mood disorder is to be coded separately. It should be pointed out that there is no solid evidence for the 
requirement of a weight gain of at least 10% within one or more major depressive episodes within a six month 
period for the diagnosis of Obesity arising from or aggravated by major depressive disorder. For this reason, no 
precise estimate is available for the frequency of this disorder; in addition, the course of Obesity arising from or 
aggravated by major depressive disorder warrants research. The reason for inclusion of Obesity arising from or 
aggravated by major depressive disorder in ICD-11 is the sizeable proportion of patients with obesity who 
report a strong association of their disorder with an episode of major depression; furthermore, this subgroup 
may have other metabolic risk factors.  
Obesity arising from or aggravated by immobilization/inactivity 
The diagnosis of Obesity arising from or aggravated by immobilization/inactivity requires 1) a BMI ≥ 30 kg/m² 
in adults or ≥ 95th centile in children and adolescents and elevated adiposity, 2) a noticeable and clinically 
relevant weight gain exceeding 10% of body weight within 6 months, 3) the weight gain cannot be attributed 
to another etiological factor. Patients of all ages with Obesity arising from or aggravated by immobilization/
inactivity initially suffer an injury or a disease, which within a short period of time leads to a state of relative 
immobilization. Patients are thus not able to continue their physically active lifestyle. Whereas fat free mass is 
lost, fat mass increases. In older individuals, Obesity arising from or aggravated by immobilization/inactivity 
also includes individuals who have become physically inactive without a defined cause; as such this category 
overlaps with sarcopenic obesity. 
The result of the injury (e.g. bone fracture) or the disease should be coded separately. It should be pointed out 
that there is no scientific evidence for the arbitrary requirement of a weight gain of at least 10% within a 
6-month period for the diagnosis of Obesity arising from or aggravated by immobilization/inactivity. For this 
reason, no precise estimate is available for the frequency of this disorder; in addition, the course of Obesity 
arising from or aggravated by immobilization/inactivity warrants research. The reason for inclusion of Obesity 
arising from or aggravated by immobilization/inactivity in ICD-11 is the sizeable proportion of patients with 
obesity who report a strong association of their immobilization/inactivity with a noticeable and clinically 
relevant weight gain. In addition, in older individuals the overlap with sarcopenic obesity is clinically useful to 
acknowledge the particular health risks inherent to loss of fat free mass in combination with an increase in fat 
mass.  
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 The proposed classification is based on our current knowledge as to specific mechanisms 
underlying the development of obesity, which currently have been elucidated to a small 
extent only. The classification centers on three dimensions: 1) etiology, 2) degree of adiposity, 
and 3) health risk. 
 1  Etiology:  Patients with obesity not due to a known certain defined etiological factor are 
to be diagnosed with ‘Obesity, multifactorial’; the respective definition pays reference to 
the complexity of this disease, which arises from environmental and genetic risk factors 
in addition to gene-gene, gene-environment and genome-environment interactions. 
Table 5. Continued
07 Obesity
Obesity attributable to more than one certain defined etiological factor
The diagnosis of Obesity attributable to more than one certain defined etiological factor requires 1) a BMI ≥ 30 kg/
m² in adults or ≥ 95th centile in children and adolescents and elevated adiposity as a result of a noticeable and 
clinically relevant weight gain which may be attributable to any combination of the diseases/conditions listed 
under the parent Obesity attributable to a certain defined factor. In light of the applicability of more than one 
factor the clinician is not able to unequivocally delineate a single factor underlying the weight gain. Examples 
include a noticeable and clinically relevant weight gain in 1) patients with major depressive disorder, who are 
concomitantly treated with a drug known to induce weight gain, 2) patients who experienced an immobilization 
and suffer from major depressive disorder. 
Obesity due to monogenic disease/genetic syndrome 
The diagnosis of Obesity due to monogenic disease/genetic syndrome requires 1) a BMI ≥ 30 kg/m² in 
adults or ≥ 95th centile in children and adolescents and elevated adiposity as a result of a noticeable and 
clinically relevant weight gain that is related to the respective monogenic disorder/genetic syndrome, 2) 
the respective monogenic disease/genetic syndrome is known to causally underlie the development of 
obesity or to show a strong association with obesity, 3) the weight gain cannot be attributed to another 
etiological factor. 
Obesity due to monogenic disease/genetic syndrome explains only a small fraction of patients with obesity. 
Dysmorphic features and/or other somatic symptoms (e.g. infertility) and/or a reduced cognitive 
functioning in combination with obesity may give rise to the suspicion of an underlying syndrome. These 
diseases may be due to chromosomal aberrations (e.g. Down syndrome), contiguous gene syndromes (e.g. 
Prader-Willi syndrome) or monogenic diseases (e.g. functionally relevant mutations in the leptin or 
melanocortin-4 receptor genes). Some of the respective diseases/syndromes are exceedingly rare and have 
in some cases (e.g. leptin deficiency due to functionally relevant mutations in the leptin or leptin receptor 
genes) been detected worldwide in a few families only. In contrast, functionally relevant mutations in the 
MC4R have been identified in one to five percent of individuals with (extreme) obesity. All other distinct 
forms of obesity due to chromosomal aberrations, contiguous gene syndromes or monogenic diseases are 
infrequent to rare. 
Pre-obesity of any etiology
The diagnosis of Pre-obesity is based on 1) the occurrence of disease strongly related to adiposity, 2) an elevated 
degree of adiposity and/or visceral adiposity, and 3) a BMI in the range of 25.0 to 29.9 kg/m²; if clearly warranted 
the diagnosis may be extended to patients with a BMI < 25 kg/m². Relevant diseases include hypertension, 
dyslipidemia, metabolic syndrome, nonalcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus, myocardial 
infarction and stroke. Both the degree of adiposity and the regional fat distribution need to be assessed using 
appropriate measures/techniques. The clinician should make use of the etiological subcategorizations of obesity 
to potentially identify a certain defined etiological factor. The disease strongly related to adiposity requires 
separate coding.  
In children and adolescents, Pre-obesity (BMI centile between 85 and 95 or 90 and 97 in Caucasian populations) is 
to be additionally diagnosed in patients with any type of metabolic and/or cardiovascular risk factor associated 
with an elevated adiposity.    
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‘Obesity attributable to a certain defined etiological factor’ is overall less frequent than 
‘Obesity, multifactorial’; for all categories within ‘Obesity attributable to a certain defined 
etiological factor’, we posit that the respective patients must have a BMI equal to or above 
the age appropriate cutoff and an elevated adiposity; in addition, the weight gain entailing 
a BMI at or above the respective age-appropriate threshold must be noticeable and 
clinically relevant. Importantly, within ‘Obesity attributable to a certain defined etiological 
factor’ we refer to ‘Obesity, iatrogenic’ to alert a physician as to the possibility that obesity 
can arise as a consequence of the intake of specific drugs or other medical procedures. 
Because of the comparably common side effect of weight gain for different medications 
and the amenability to potential treatment via discontinuation of the respective drug, we 
maintain reference to ‘Obesity arising from or aggravated by drug induced weight gain’, 
despite the fact that drug side effects cannot readily be considered as diseases.  
Table 5. Continued
07 Obesity
Dimension 2: Degree of adiposity 
Obesity in adults is subdivided into six different classes (I–VI; see below); this sub-classification is useful for defining 
subgroups eligible for particular treatments (e.g. bariatric surgery). The staging recognizes the fact that rates of extreme 
obesity have increased substantially in many countries over the last decades. 
Obesity class I
The adult BMI is in the range of 30.0 to 34.9 kg/m². Medical risks associated with obesity are slightly elevated in 
comparison to individuals with a normal weight.
In children and adolescents the BMI is in between the +2 and +3 standard deviation of an appropriate reference 
population.   
Obesity class II
The adult BMI is in the range of 35.0 to 39.9 kg/m². Medical risks associated with obesity are elevated in comparison 
to individuals with a normal weight.
In children and adolescents the BMI is in between the +3 and +4 standard deviation of an appropriate reference 
population.   
Obesity class III
The adult BMI is in the range of 40.0 to 44.9 kg/m². Medical risks associated with obesity are substantially elevated in 
comparison to individuals with a normal weight.
In children and adolescents the BMI is in between the +4 and +5 standard deviation of an appropriate reference 
population.   
Obesity class IV
The adult BMI is in the range of 45.0 to 49.9 kg/m². Medical risks associated with obesity are substantially elevated in 
comparison to individuals with a normal weight.
In children and adolescents the BMI is in between the +5 and +6 standard deviation of an appropriate reference 
population.   
Obesity class V
The adult BMI is in the range of 50.0 to 54.9 kg/m². Medical risks associated with obesity are substantially elevated in 
comparison to individuals with a normal weight.
In children and adolescents the BMI is in between the +6 and +7 standard deviation of an appropriate reference 
population.   
Obesity class VI
The adult BMI exceeds 55.0 kg/m². Medical risks associated with obesity are substantially elevated in comparison to 
individuals with a normal weight.
In children and adolescents the BMI equals or is above the seventh standard deviation of an appropriate reference 
population.   
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2  Degree of Adiposity:  The BMI threshold for adult obesity is 30 kg/m²; obesity in children 
is generally diagnosed if the BMI equals or is in excess of the age- and sex-specific 95th 
or 97th centile. Cutoffs may vary by country, however, and different values may apply to 
non-Caucasian populations. The dimensional categorization of different classes of obesity 
extends the WHO categorization to a total of six classes. We deem this extension relevant 
because of the secular increase of extreme degrees of obesity and to allow a better staging 
of patients with such an extreme degree of adiposity. For children and adolescents, our 
classification scheme is based on multiples of the standard deviation score (SDS- or 
z-scores).  
3  Health Risk:  Because of the difficulties inherent to the assessment of health risks via BMI 
alone, the health risk of an obese patient requires further specification. While we realize 
that such an assessment is highly complex and dependent on age, sex and ethnicity among 
other variables, we nevertheless deem it necessary to provide the physician with a 
general rule of thumb as to how to assess the health risk of an individual obese patient. 
Research is warranted to better quantify the interactions of the different factors used to 
assess health risk; furthermore, physicians should be provided with tools (e.g. ,algorithms, 
software programs) to more reliably and validly assess the health risk.   
 Conclusion 
 Obesity is a complex disease, which in the majority of patients has a multifactorial basis; 
obesity can be (largely) attributable to a certain defined etiological factor in a minority of 
patients. In many populations worldwide prevalence rates of obesity exceed 20% in both 
males and females. The ICD-10 and ICD-11 Beta Draft definitions of obesity do not reflect our 
current knowledge of this disease; unsystematic definitions entail the possibility that clini-
cians will not diagnose the respective disease and/or that the diagnosis is deemed clinically 
irrelevant, thus precluding a patient-oriented focus to address the disease. The listing of over-
weight and obesity within the parent ‘Endocrine, nutritional and metabolic diseases’ is not 
readily compatible with the complexity of obesity; this particularly holds true for the listing 
Table 5. Continued
07 Obesity
Dimension 3: Health risk
A staging according to health risk is of crucial importance to assess the health implications of obesity with respect to age, sex, 
ethnicity, and family history. Such a staging needs to take current knowledge of obesity/adiposity related health risks into 
account. The proposed staging system requires systematic validation in prospective population based studies; as such the 
staging system must be considered as preliminary.  
Low
The absence of risks and obesity/adiposity related diseases delineated in the intermediate and high health risk stages
Intermediate
1) positive family history for adiposity related disease (primarily type 2 diabetes mellitus, hypertension, myocardial 
infarction, stroke) in first degree relatives, 2) Obesity class ≥ 1 in patients aged ≤ 30 and obesity class ≥2 in patients 
aged ≥ 30, 3) visceral obesity, 4) evidence of impaired glucose tolerance, 5) hypertension, 6) hypercholesterolemia 
and/or hypertriglyceridemia, 7) regular tobacco use, 8) physical inactivity. 
High
1) type 2 diabetes mellitus, 2) metabolic syndrome, 3) cardiovascular/renal end organ damage, 4) obesity related 
musculoskeletal disorders that significantly impinge health
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within the subcategory ‘Nutritional diseases’. For this purpose, we suggest that the common 
disease obesity is listed as an overarching parent category, thus obliterating the need to 
classify this disease within a biologically and medically misleading context. The definitions of 
the current Beta Draft are very crude for the overarching parents and become more and more 
detailed as the respective diagnoses become rarer. The opposite should apply: common diag-
noses need to be explained in more detail to allow the clinician to make use of the information 
to better diagnose and treat patients. The proposed EASO classification aims to overcome the 
negligence that obesity has had in the past with respect to its diagnosis. Our proposal is based 
on current knowledge, uses common medical terminology, and allows a clinician to both 
consider etiological and quantitative aspects. Whereas the classification of different classes 
of obesity is based on BMI, the definition pays adherence to the necessity to assess adiposity 
and regional fat distribution. Importantly, we focus on obesity and recommend that ‘Pre-
obesity’ in the BMI range of < 30 kg/m² is included in ICD-11 only if adiposity-related meta-
bolic and/or cardiovascular diseases are manifest in the respective patient. Our definitions 
repeatedly allude to the age of a patient; a particular BMI in the overweight range is of greater 
medical concern in a younger than an older patient. Finally, we need to circumvent any ambi-
guity with respect to our definitions of overweight and obesity; we propose to stick to the 
categorization proposed by the WHO in 2000  [2] , according to which overweight is defined 
via a BMI  ≥ 25 kg/m²; accordingly, obesity defined via a BMI  ≥ 30 kg/m² represents a 
subgroup of overweight associated with a substantially elevated fat mass. EASO perceives the 
dire need to better anchor the diagnosis of obesity within ICD to benefit patients. EASO recom-
mends that societies as a whole strive to reduce the obesogenic environment and help indi-
viduals with obesity overcome stigmatization. Healthcare professionals need to make knowl-
edgeable of our current understanding of obesity to help guide individuals with obesity and 
to offer warranted diagnostic assessments and treatment.
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